Clinical Trial Details
| Trial ID: | L2897 |
| Source ID: | NCT05073692 |
| Associated Drug: | Su |
| Title: | Comparison of Type 2 Diabetes Pharmacotherapy Regimens |
| Acronym: | ON TARGET DM |
| Status: | RECRUITING |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus|Cardiovascular Diseases |
| Interventions: | DRUG: SU|DRUG: DPP4|DRUG: SGLT2i|DRUG: GLP-1RA|DRUG: SGLT2i or GLP-1RA|DRUG: Linagliptin (DPP4)|DRUG: Exenatide (GLP-1RA)|DRUG: Liraglutide (GLP-1RA)|DRUG: Empagliflozin (SGLT2i)|DRUG: Glimepiride (SU)|DRUG: Glipizide (SU)|DRUG: Glimepiride (SU) or Glipizide (SU)|DRUG: SU or DPP4 (excluding saxagliptin and alogliptin)|DRUG: Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) |
| Outcome Measures: | Primary: Incidence of 3-point Major Adverse Cardiovascular Events (MACE), 3-point MACE is defined as a single outcome measure, which is a composite measure of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular disease death., 1/1/2014 to 6/30/2021 | |
| Sponsor/Collaborators: | Sponsor: Kaiser Permanente | Collaborators: Geisinger Clinic|Henry Ford Health System|HealthPartners Institute|Patient-Centered Outcomes Research Institute |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 270000 |
| Study Type: | OBSERVATIONAL |
| Study Designs: | Observational Model: |Time Perspective: p |
| Start Date: | 2021-07-01 |
| Completion Date: | 2025-08-31 |
| Results First Posted: | |
| Last Update Posted: | 2024-10-24 |
| Locations: | Romain S. Neugebauer, Oakland, California, 94612, United States|Kaiser Permanente Southern California, Pasadena, California, 91101, United States|Kaiser Permanente Hawaii, Honolulu, Hawaii, 96817, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|HealthPartners Institute, Bloomington, Minnesota, 55425, United States|Geisinger, Danville, Pennsylvania, 17821, United States |
| URL: | https://clinicaltrials.gov/show/NCT05073692 |
